MIST

Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:MIST

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/22	21:00	GlobeNewswire Inc.	Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/05/13	20:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/05/13	19:59	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/03/04	23:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/03/02	06:52	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/29	21:00	GlobeNewswire Inc.	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/29	06:37	GlobeNewswire Inc.	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/26	21:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/15	10:56	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/14	21:10	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/12/26	22:54	Dow Jones News	Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/12/26	21:57	Dow Jones News	Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/12/26	21:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/21	21:00	PR Newswire (Canada)	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/21	21:00	PR Newswire (US)	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	21:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	20:57	PR Newswire (Canada)	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	20:57	PR Newswire (US)	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	20:37	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	20:09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/12	00:00	PR Newswire (US)	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/12	00:00	PR Newswire (Canada)	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/10	06:43	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/07	23:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/07	21:00	PR Newswire (US)	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/07	21:00	PR Newswire (Canada)	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/10/25	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/10/24	20:00	PR Newswire (US)	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/10/24	20:00	PR Newswire (Canada)	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/10/06	20:00	PR Newswire (US)	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:MIST	Milestone Pharmaceuticals Inc